Heart failure & cardiomyopathiesResearch article
Seated Pulmonary Artery Pressure Management in Patients With Heart Failure
- Single-arm clinical trial
- open-label
- multicentre
- 75 European and US centres
- performance goal
- Enrolment February 7, 2020, to March 31, 2023
Authors' conclusion
Remote HF management using seated mPAP and vital signs in NYHA functional class III patients is safe and results in a low rate of HF hospitalizations and mortality over 12 months.
Study context
- Population
- Heart failure (HF) patients with NYHA class III symptoms, irrespective of EF, and recent HF hospitalization and/or elevated natriuretic peptidesmodified ITT cohort
- Participants
- 456 patients
- Comparison
- Remote HF management with seated mean pulmonary artery pressure (mPAP) vs performance goal
- Cordellan = 456
Main finding
As reported in the abstract
HF hospitalization or all-cause mortality rate (prespecified, powered, secondary effectiveness endpoint) · 12 months
12-month event rate (events/patient/12 months)
0.36 (95% CI: 0.31-0.42)
Significantly lower than performance goal of 0.70 (0.36 vs 0.70)
P < 0.0001
Safety
Device/system-related complications and pressure sensor failures · 12 months
- Device/system-related complications (none beyond 6-month primary results)
- 0.8%
- Pressure sensor failures (none beyond 6-month primary results)
- 0.2%
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Seated Pulmonary Artery Pressure Management in Patients With Heart Failure. JACC Heart Fail. Published 13 February 2026. doi:10.1016/j.jchf.2025.102847
Summarised from the published abstract; every number is checked against it